Archives
-
BIRB 796 Workflow for p38α MAPK Studies
2026-08-28
BIRB 796, also called Doramapimod, combines subnanomolar p38α engagement with an allosteric mechanism suited to inflammation, cytokine, and apoptosis workflows. This guide translates that profile into practical assay design, phosphatase-aware experiments, and troubleshooting strategies for reproducible research.
-
AP20187 Chemical Inducer of Dimerization Guide
2026-08-27
AP20187 enables time-controlled activation of engineered signaling proteins, making it useful for conditional gene expression, cell therapy, and metabolic assays. This guide connects practical CID workflows with a chronic intermittent hypoxia model to show how programmable activation can strengthen macrophage–nociceptor experiments without overstating the reference study’s findings.
-
Primidone Inhibits TRPM3 in Adenomyosis
2026-08-27
A 2025 study links increased TRP-channel expression with adenomyosis symptoms and tests Primidone as a pharmacological intervention in a tamoxifen-induced mouse model. The work identifies TRPM3 as a plausible analgesic and disease-modifying target while highlighting the need for clinical validation, target-engagement studies, and better dose translation.
-
CTCF, Centromere Function, and Mitotic Fidelity
2026-08-26
The reference study uses rapid, inducible CTCF degradation to show that CTCF maintains centromere mechanics, metaphase plate organization, accurate mitosis, and post-mitotic nuclear shape. Its findings distinguish CTCF loss from primary CENP-E recruitment defects and support a model in which CTCF contributes to centromeric chromatin function, potentially alongside cohesin.
-
GW4064: Practical FXR Activation Workflows
2026-08-26
GW4064 is a potent non-steroidal FXR agonist for separating receptor activation from downstream bile acid, lipid, and barrier phenotypes. This workflow-focused guide shows how to build reproducible FXR assays, test transporter rescue, and troubleshoot solubility, light sensitivity, and vehicle effects.
-
EZ Cap™ Mouse IL-12 mRNA: Research Workflow
2026-08-25
Build controlled mouse IL-12 expression studies with a capped, polyadenylated, m1Ψ-modified transcript designed for efficient translation and reduced innate RNA sensing. The workflow connects routine cell assays with emerging extrahepatic delivery platforms, including virus-mimicking particles for lung and spleen research.
-
Epalrestat Workflows for Polyol Pathway Research
2026-08-25
Build reproducible Epalrestat experiments for aldose reductase inhibition, diabetic complication studies, oxidative stress research, and neuroprotection. A practical workflow also shows how the compound can support hypothesis-driven cancer metabolism assays without overstating the current evidence.
-
GSK-923295: CENP-E Inhibition Workflows
2026-08-24
GSK-923295 provides a precise pharmacological route to study CENP-E-dependent chromosome congression, mitotic arrest, and tumor-cell response. This guide connects dose-response assays with the centromere-focused findings from CTCF depletion studies, while emphasizing solvent control, timing, imaging, and interpretation.
-
MK 0893: Discovery of a Glucagon Receptor Antagonist
2026-08-24
The reference study describes how lead optimization of a pyrazole-based scaffold produced MK 0893, a potent and selective competitive glucagon receptor antagonist with oral activity in diabetic animal models. Its combination of nanomolar receptor and cAMP potency, family B GPCR selectivity, and glucose-lowering efficacy established a useful foundation for type 2 diabetes research.
-
GSK J4 HCl: Practical Epigenetic Workflows
2026-08-23
GSK J4 HCl enables cell-based interrogation of JMJD3-linked H3K27 demethylation in inflammation, cancer, and chromatin-regulated transcription. This guide translates its prodrug behavior into practical dose selection, promoter-level assays, and troubleshooting strategies, while distinguishing direct evidence from exploratory applications.
-
Metabolomics Reveals Carbapenemase Resistance
2026-08-22
The reference study shows that LC-MS/MS profiling of intracellular and extracellular metabolites can distinguish carbapenemase-producing Enterobacterales from non-CPE isolates after short, antibiotic-free growth. Its combination of metabolite biomarkers, supervised machine learning, and pathway analysis offers a potential route to faster resistance detection while also highlighting metabolic features associated with the resistant phenotype.
-
Fangchinoline Restores Lysosomal Defense Against H1N1
2026-08-22
Cheng and colleagues identify fangchinoline as a lysosome-targeted antiviral that restores TFEB-dependent lysosomal gene expression and interferes with H1N1 entry. By combining Connectivity Map screening, transcriptomics, organelle assays, stage-resolved infection experiments, and in vivo validation, the study defines a host-directed strategy for countering influenza-associated lysosomal dysfunction.
-
GSK-923295 and the Mechanics of Mitotic Fidelity
2026-08-21
GSK-923295 is a CENP-E inhibitor for dissecting chromosome congression, mitotic arrest, and centromere-dependent fidelity. This article distinguishes motor inhibition from CTCF-linked centromere architecture defects to improve assay interpretation and cancer research design.
-
Coumestrol C5832: Reliable Cell Assays
2026-08-20
Learn how Coumestrol (SKU C5832) can support better-controlled viability, proliferation, estrogen-receptor, and ferroptosis experiments. This scenario-based guide connects product specifications with published RA-fibroblast-like synoviocyte findings while emphasizing solvent controls, orthogonal readouts, and interpretation limits.
-
CKI 7 Dihydrochloride: Assay Logic for CK1
2026-08-20
Explore how CKI 7 dihydrochloride can support mechanistic Casein kinase 1 inhibitor studies across Wnt, circadian, apoptosis, and cancer models. This guide emphasizes causal assay design and explains why CK1 perturbation should not be conflated with the MAPK10–KRT16 metastasis pathway.